Inhibrx, Inc. announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. to holders of shares of the Company’s common stock on a pro rata basis.
May 10, 2024
· 12 min read
